NCT01953926: An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

NCT01953926
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Endocrine (Hormone Therapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic or unstable brain metastases
https://ClinicalTrials.gov/show/NCT01953926

Comments are closed.

Up ↑